Latest Conference Articles

January 28th 2021, 8:52pm

IASLC World Conference on Lung Cancer

January 28, 2021 - Rapid, high, and uniform brain exposure was seen with [11C]osimertinib, followed by a reduction in total brain metastases volume with oral administration of the EGFR TKI in patients with EGFR-mutant non–small cell lung cancer and brain metastases.

January 28th 2021, 8:46pm

IASLC World Conference on Lung Cancer

January 28, 2021 - NRG1 fusions are detectable in patients with non–small cell lung cancer, providing a rationale to perform larger, retrospective studies assessing therapeutic outcomes in patients with NRG1 fusion–positive tumors and evaluate afatinib in this patient subgroup.

January 28th 2021, 8:44pm

IASLC World Conference on Lung Cancer

January 28, 2021 - Immuno-oncology therapies provided significant potential health gains for both patients and the population, although age should be taken into account to improve accuracy and avoid bias.

January 28th 2021, 7:53pm

IASLC World Conference on Lung Cancer

January 28, 2021 — Frontline pembrolizumab continued to demonstrate clinically meaningful improvements in overall survival, overall response rate, and time to progression on next-line therapy compared with platinum-based chemotherapy in patients with locally advanced or metastatic PD-L1–positive non–small cell lung cancer without sensitizing EGFR or ALK mutations.

January 28th 2021, 6:28pm

World Conference on Lung Cancer

January 28, 2021 - Pembrolizumab continued to demonstrate a clinically meaningful improvement in overall and progression-free survival, compared with docetaxel, in patients with previously treated, PD-L1–positive advanced non-small cell lung cancer after more than 5 years of follow-up.

January 28th 2021, 5:44pm

World Conference on Lung Cancer

January 28, 2021 - The addition of apatinib to single agent chemotherapy showed promising efficacy and was found to be well tolerated in patients with pretreated advanced small cell lung cancer.

January 28th 2021, 5:40pm

IASLC World Conference on Lung Cancer

January 28, 2021 - Although survivors and patients with lung cancer felt that they were involved in the treatment decision-making process, nearly half of them reported that they knew what their treatment options were before making a decision.

January 28th 2021, 5:31pm

IASLC World Conference on Lung Cancer

January 28, 2021 — Pembrolizumab in combination with chemotherapy continued to show improved overall survival and progression-free survival compared with chemotherapy alone in patients with previously untreated metastatic nonsquamous non–small cell lung cancer.

January 18th 2021, 4:27pm

Gastrointestinal Cancers Symposium (ASCO GI)

Single-agent pembrolizumab demonstrated durable antitumor activity among patients with treatment-naïve hepatocellular carcinoma, suggesting that the checkpoint inhibitor may have additional utility in this space, according to findings from a phase 2 trial presented during the 2021 Gastrointestinal Cancers Symposium.

January 18th 2021, 12:05am

Gastrointestinal Cancers Symposium (ASCO GI)

January 17, 2021 - Pembrolizumab demonstrated maintained numerical improvements in overall survival and progression-free survival compared with placebo in patients with previously treated advanced hepatocellular carcinoma.

January 17th 2021, 11:35pm

Gastrointestinal Cancers Symposium (ASCO GI)

January 17, 2021 - The combination of atezolizumab and bevacizumab continued to display improved survival compared with sorafenib in previously untreated patients with advanced hepatocellular carcinoma.

January 17th 2021, 8:55pm

Gastrointestinal Cancers Symposium (ASCO GI)

January 17, 2021 - Axitinib plus octreotide LAR failed to demonstrate a significant improvement in progression-free survival (PFS) compared with placebo plus octreotide LAR in patients with advanced G1-2 extra-pancreatic neuroendocrine tumors.

January 17th 2021, 7:37pm

Gastrointestinal Cancers Symposium (ASCO GI)

January 17, 2021 - Infigratinib was found to be associated with encouraging clinical activity with a manageable safety profile in patients with chemotherapy-refractory cholangiocarcinoma whose tumors harbor FGFR2 fusions.

January 17th 2021, 7:23pm

Gastrointestinal Cancers Symposium (ASCO GI)

January 17, 2021 — Ivosidenib tablets led to a 21% reduction in the risk of death compared with placebo in previously treated patients with IDH1-mutant cholangiocarcinoma, according to the final overall survival analysis of the phase 3 ClarIDHy trial.

January 17th 2021, 4:07pm

Gastrointestinal Cancers Symposium (ASCO GI)

James J. Harding, MD, discusses the results of the ongoing, phase 2 SUMMIT basket trial in HER2-mutant advanced biliary tract cancers.

January 17th 2021, 4:04pm

Gastrointestinal Cancers Symposium (ASCO GI)

Andrew Zhu, MD, PhD, discusses the final overall survival results from the phase 3 ClarIDHy trial in previously treated patients with IDH1-mutated cholangiocarcinoma.

January 17th 2021, 1:35am

Gastrointestinal Cancers Symposium (ASCO GI)

January 16, 2021 - Trifluridine/tipiracil, when used in combination with bevacizumab, led to an improvement in overall survival over capecitabine/bevacizumab in the frontline treatment of patients with unresectable metastatic colorectal cancer who are not eligible for standard chemotherapy.

January 16th 2021, 8:00pm

Gastrointestinal Cancers Symposium (ASCO GI)

Zev A. Wainberg, MD, of University of California, Los Angeles, discusses the results of the phase 2 FIGHT trial (NCT03343301) in FGFR2b-positive gastric/gastroesophageal junction (GEJ) cancer.

January 16th 2021, 7:11pm

Gastrointestinal Cancers Symposium (ASCO GI)

January 16, 2021 - Lenvatinib monotherapy was found to be effective in patients with unresectable hepatocellular carcinoma in the United States.

January 16th 2021, 7:00pm

Gastrointestinal Cancers Symposium (ASCO GI)

Vivek Subbiah, MD, of The University of Texas MD Anderson Cancer Center, discusses the clinical activity of pralsetinib (Gavreto) in RET fusion-positive pancreatic cancer and cholangiocarcinoma.